Full Breakdown
Record-Breaking Pig Kidney Transplant Bridges Patient to Human Organ
9/8/2026, 4:32:41 AM
Core Event: 271-Day Pig-Kidney Bridge
On January 25, 2025, surgeons at Massachusetts General Hospital transplanted a gene-edited pig kidney into Tim Andrews, a 66-year-old with end-stage renal disease from type-2 diabetes. The xenograft functioned for 271 days, keeping Andrews off dialysis until a deceased-donor human kidney was implanted on January 13, 2026. The case, reported in *The Lancet* on September 3, is the first documented transition from a porcine to a human kidney in a living recipient.
Background & Context
Human kidney demand far exceeds supply; more than 100,000 Americans await a transplant. Earlier MGH xenotransplant attempts in 2024 achieved 52-day and 130-day survivals, prompting researchers to enroll less critically ill candidates. Andrews participated under an FDA Expanded Access IND.
Data & Statistics
- 271 days of dialysis-free survival with the pig kidney.
- 9 % probability of receiving a human kidney within five years (research estimate).
- 40 % risk of death or removal from the waiting list without a transplant (research estimate).
- The organ incorporated 69 gene edits: removal of three pig antigen genes, insertion of seven human genes, and inactivation of 59 porcine endogenous retrovirus copies (eGenesis).
- Early T-cell-mediated rejection was treated; later microvascular injury led to organ failure and removal in October 2025.
- After removal, Andrews underwent about 82 days of dialysis before the human transplant.
Official Statements & Responses
Lead author Dr. He described xenotransplantation as a “bridge” to keep patients off dialysis while awaiting a human donor, with the longer-term goal of establishing safety for possible permanent use. The team reported no detection of pig-derived viruses, no new anti-human antibodies, and no interference with the subsequent human graft.
On-the-Ground Report
Andrews expressed gratitude, noting the transplant restored everyday activities such as walking his dog and fishing. He also said receiving an organ from a young donor gave him a sense of responsibility to honor the gift.
Verbatim Quotes
- “Our vision is that xenotransplantation could help address this gap — initially as a bridge to get patients off dialysis while they wait for a human donor kidney, and potentially, as we establish long-term safety and durability, as a destination therapy in its own right,” — Dr. Leonardo Riella
- “Every day I wake up. I’m like, (this is) another (extra) day because I should have been dead a year ago or more,” — Tim Andrews
What’s Next
The eGenesis platform (EGEN-2784) is slated to enter an FDA-cleared clinical trial in early 2027, expanding the number of patients receiving genetically engineered pig kidneys. Researchers will study longer-term outcomes, refine immunosuppressive regimens, and monitor vascular injury to determine whether xenotransplantation can move from a bridge therapy to a durable treatment option.
